GHK-Cu: Topical vs Injectable Evidence and Safety

GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) found in human blood. It binds copper ions strongly and forms the complex GHK-Cu. Tissue levels are reported to decline with age, though the size and clinical relevance of that decline rest substantially on the work of the peptide's discoverer.

GHK-Cu is an established topical cosmetic ingredient and is widely used in anti-wrinkle products. Injectable use is a separate question: it is not an approved or validated route, and it has no human efficacy or safety data.

In cell-culture and animal models, GHK-Cu has been associated with changes in extracellular-matrix turnover (collagen and elastin production and the balance of matrix-degrading enzymes), anti-inflammatory signaling, and broad changes in gene expression linked to tissue repair. A review also cites preliminary mouse observations on cognitive impairment in aging.

These findings come mostly from laboratory work such as human fibroblast cultures. They are hypotheses about how the molecule might act, not demonstrated effects in people.

Topical use: clinical data are confined to small, short, low-quality cosmetic studies, several conducted or sponsored by groups with a commercial interest in copper-peptide products. A 2025 review of topical GHK as an anti-wrinkle ingredient noted a surprising absence of clinical studies and found the published information on skin permeability and effectiveness insufficient. An earlier 2008 review by Pickart, written from a skin-care company, describes controlled studies on aged skin, but well-controlled clinical trials are still absent.

Injected use: there are no human efficacy or safety data. Roles sometimes attributed to GHK-Cu in hair growth, wound healing, cognition or anti-cancer activity are not supported by human randomized trials and remain preclinical or theoretical.

For injected GHK-Cu, FDA says compounded products may carry a risk of immune reactions (immunogenicity) because the peptide can aggregate, may contain peptide-related impurities, and have limited human data to inform safety. Because the complex delivers copper, cumulative copper exposure is a relevant consideration, particularly with systemic or long-term use.

Side effects of topical cosmetic use are not well characterized in the cited reviews. The absence of reported harms in small cosmetic studies does not establish long-term safety.

GHK-Cu is not approved by the FDA or Health Canada for therapeutic or injectable use. FDA's compounding safety list names it specifically for injectable routes. The 2026 WADA Prohibited List does not name GHK-Cu. Its S0 section covers any pharmacological substance not addressed elsewhere on the list and with no current approval by any government health authority for human therapeutic use, and several sections say they include substances not named.